A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorStep Pharma, SAS
About this trial
The Phase 1 part of the study is a dose escalation of STP938 as monotherapy.
The Phase 2 part of the study is cohort expansion of STP938 as a monotherapy in 5 different B and T cell lymphomas.
Eligibility criteria
Qualifiers
Signed and dated informed consent, and able to comply with the study procedures and any locally required authorization.
Male or female aged ≥ 18 years.
Relapsed/refractory patients with histologically confirmed diagnosis of B cell or T cell lymphoma
Must have received at least 2 prior systemic therapies and have no treatment options known to provide clinical benefit
Disqualifiers
Pregnant or breastfeeding females and women of child bearing potential or males unwilling to comply with contraception requirements.
Known carcinomatous meningitis or central nervous system (CNS) involvement with lymphoma.
Active malignancy within 2 years of study enrollment
Prior radiation or surgical resection of their lymphoma without additional sites of measurable disease outside of the radiation field or subjects who have received prior radiation or surgical resection of their lymphoma ≤2 weeks prior to the first dose of study drug.
Trial design
Treatments tested in this trial
- STP938
Treatment groups
180 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov